Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung Cancer.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell...

Next Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Novo Nordisk aims for market domination, boasts $1.5bn ...

May 3, 2024

Opinion: Surfing, camping, and deciding when to stop: Australia’s human-centric approach to dialysis

Opinion: Surfing, camping, and deciding when to stop: A...

Aug 25, 2023

Plus Therapeutics and PPS expand partnership for cGMP drug production

Plus Therapeutics and PPS expand partnership for cGMP d...

May 2, 2023